About
Technology
Issues
FAQ
Links
Official Page
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.